Momenta Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock
Press Release Source: Momenta Pharmaceuticals On Tuesday December 7, 2010, 4:12 pm
CAMBRIDGE, Mass., Dec. 7, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA - News), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it intends to offer its common stock in a registered underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
UBS Investment Bank is acting as the sole underwriter for the offering.
The shares will be issued pursuant to a shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission. A preliminary prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission. Copies of the preliminary prospectus supplement relating to these securities may be obtained from UBS Investment Bank, Attention: Prospectus Department, 299 Park Avenue, New York, NY 10171, or by calling 888-827-7275. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Momenta Pharmaceuticals, Inc., nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Momenta
There are times when rules and precedents cannot be broken; others when they cannot be adhered to with safety. (Thomas Joplin)
AI
